Journal September 27, 2026 6 min read

What does the research say about skin hydration?

Skin hydration research spans oral collagen peptides, ergothioneine, topical emollients and injectable boosters. Here is what the clinical and preclinical evidence actually reports, and where it is animal-only or in vitr

peptides-pro Editorial

Skin hydration is the water content of the stratum corneum and the capacity of the epidermis to retain it, and it is measured in the research literature chiefly as corneometry (electrical capacitance of the skin surface) and as transepidermal water loss (TEWL), the outward flux of water through the skin barrier. The compounds studied in this context are heterogeneous: they include oral collagen peptides and collagen tripeptides, the amino acid derivative ergothioneine, topical panthenol/niacinamide/glycyrrhizate emollients, hyaluronate-based injectables, and topical growth-factor and hydrogel formulations. Identifiers vary by compound class — collagen peptides are defined by peptide length and hydrolysis source rather than a single formula, ergothioneine is a betaine of 2-thio-L-histidine, and hyaluronate products are defined by molecular weight and degree of crosslinking.

The mechanistic work centres on the epidermal barrier and its lipid–protein matrix, with downstream readouts in the cornified layer and, for injectable and topical formulations, on dermal extracellular matrix turnover and local microcirculation.

Research Studies

Oral collagen peptides and skin hydration in human studies

A narrative review evaluated the human evidence on oral collagen supplementation, particularly collagen peptides, for skin, hair, nail and wound-healing outcomes [4]. Collagen is described as a key structural protein of the skin, required for mechanical strength, elasticity and hydration, and oral collagen peptides have drawn interest as a nutritional strategy. The review reports that the evidence base is heterogeneous, and it frames its aim as summarizing and critically evaluating the current human evidence rather than establishing a uniform effect [4].

AP collagen peptide and skin hydration in a mouse model of oxazolone-induced atopic dermatitis

AP collagen peptide (APCP), which contains collagen tripeptide (CTP), was evaluated in an oxazolone-induced atopic dermatitis-like model in hairless mice [2]. Atopic dermatitis is characterized by impaired barrier function and Th2-mediated immune responses, and the study assessed skin hydration and transepidermal water loss alongside inflammatory responses under conditions of barrier dysfunction [2]. This is an animal model; findings in hairless mice are not human outcomes.

Ergothioneine and skin hydration in healthy adults aged 40 to 65

A randomized, double-blind, placebo-controlled trial is evaluating NVTIA® Ergothioneine, a branded ergothioneine ingredient, in healthy adults aged 40 to 65 years [1]. Participants receive the ingredient or a matching placebo once daily for 12 weeks. The primary objective concerns biomarkers of oxidative stress and healthy aging; skin elasticity, skin hydration and inflammatory biomarkers are secondary objectives, alongside safety [1]. Because hydration is a secondary endpoint, the trial is not designed to test hydration as its primary hypothesis.

L-carnosine-containing hyaluronate injection and facial skin hydration

A randomized, controlled, evaluator-blinded trial examined the efficacy and safety of an L-carnosine-containing hyaluronate injection for facial skin hydration and brightness [5]. The design is controlled and the outcome assessment is evaluator-blinded, which addresses observer bias in the hydration and brightness ratings.

Topical panthenol, niacinamide and dipotassium glycyrrhizate in xerosis cutis

A 28-day randomized, intra-individual, split-leg trial tested a topical formulation containing panthenol, niacinamide and dipotassium glycyrrhizate in subjects with xerosis cutis, a condition of impaired epidermal barrier function, increased TEWL, reduced hydration and pruritus [6]. The test emollient was applied twice daily to one pretibial area while the contralateral leg remained untreated as an internal control, with assessments at baseline and follow-up [6]. The split-leg design means each participant serves as their own control.

Ariessence™ Pure PDGF+ after ablative laser

A multi-centre, post-market cosmetic evaluation is assessing a viscous leave-on topical solution applied to the full face after an ablative laser procedure, compared with an emollient control [7]. The stated aims are procedure tolerability and the appearance of the skin, with maintenance of skin hydration as an intended use of the product [7]. This is a post-market cosmetic evaluation rather than a placebo-controlled efficacy trial.

Cellbooster® Shape and skin hydration in healthy subjects with facial aging

A post-market clinical investigation is evaluating Cellbooster® Shape, a CE-marked hyaluronic-acid-based superficial epidermis/dermis injection filler and skinbooster produced with patented CHAC Technology, consisting of non-crosslinked HA with L-carnitine and vitamin C [8]. The device is designed to reduce local puffiness by improving microcirculation and hydration. Healthy subjects with signs of facial skin aging receive a 3-session treatment with follow-up over 70 days after the initial injection session, with several objective skin measurements recorded [8].

Fish collagen hydrolysates and wound healing

A patent review examined fish collagen hydrolysates in wound healing, noting that healing can be delayed by bacterial contamination, dressing irritation and internal conditions such as diabetes, and that interest has grown in dressings incorporating bioactive materials [3]. Collagen peptides from collagen hydrolysis are described as bioactive, and fish collagen has gained prominence for its profile relative to traditional sources [3]. This is a patent review, not a clinical trial, and it does not report hydration endpoints.

Comparison of study designs and hydration endpoints

Study	Model / population	Hydration role	Design
NVTIA® Ergothioneine [1]	Healthy adults 40–65	Secondary endpoint	Randomized, double-blind, placebo-controlled, 12 weeks
AP collagen peptide [2]	Hairless mice, oxazolone-induced AD-like	Primary measure	Animal model
L-carnosine hyaluronate injection [5]	Facial skin	Primary outcome	Randomized, controlled, evaluator-blinded
Panthenol/niacinamide/glycyrrhizate [6]	Xerosis cutis, pretibial	Primary outcome	Randomized, split-leg, untreated control, 28 days
Ariessence™ Pure PDGF+ [7]	Post-ablative laser, full face	Intended use	Post-market, emollient control
Cellbooster® Shape [8]	Healthy subjects, facial aging	Stated device purpose	Post-market, 3 sessions, 70-day follow-up

Supporting formulation and delivery research

Additional work addresses how hydration-relevant formulations are built and delivered. A study developed a structurally stable skin-brightening moisturizing cream using hydroxyethyl cellulose as a functional polymer additive with niacinamide as the active, characterizing the physicochemical properties and performance of the formulations [9]. A pilot study examined the safety, tolerability and functional performance of a hydrogel facial mask based on poly(N-vinyl pyrrolidone) and poly(ethylene glycol) in sensitive skin, a population in which long-term effects had been insufficiently characterized [10]. Spectroscopic characterization and molecular interaction analysis of Pentapeptide-18 examined it as an anti-aging candidate in the context of dermal extracellular matrix breakdown, wrinkle formation from repetitive facial muscle movement, and reduced collagen and elastin synthesis [11]. A retrospective study reported clinical outcomes of intense pulsed light combined with non-crosslinked sodium hyaluronate, tranexamic acid and vitamin C mesotherapy for facial photoaging, a condition involving structural and functional deterioration across multiple skin layers that single-modality treatments rarely address concurrently [12]. These are formulation, delivery and combination-protocol studies; they do not establish hydration efficacy for the actives named.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research use only, and we do not provide dosing information or medical guidance. Nothing on this page is a recommendation to use any compound. Anyone considering a compound for themselves should speak to a licensed clinician.